Edition:
United Kingdom

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Global Select Market

5.67USD
18 May 2018
Change (% chg)

$-0.27 (-4.55%)
Prev Close
$5.94
Open
$5.95
Day's High
$6.07
Day's Low
$5.60
Volume
96,080
Avg. Vol
34,927
52-wk High
$6.30
52-wk Low
$1.18

Chart for

About

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company... (more)

Overall

Beta: --
Market Cap(Mil.): $57.83
Shares Outstanding(Mil.): 21.42
Dividend: --
Yield (%): --

Financials

  APVO.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -5.29 -- --
ROI: -122.43 1.57 14.38
ROE: -145.10 2.43 16.07

BRIEF-Aptevo Therapeutics Begins Patient Dosing In Phase 2 Clinical Trial Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS BEGINS PATIENT DOSING IN PHASE 2 CLINICAL TRIAL OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA

28 Nov 2017

Earnings vs. Estimates